[go: up one dir, main page]

WO2006008008A3 - Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a) - Google Patents

Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a) Download PDF

Info

Publication number
WO2006008008A3
WO2006008008A3 PCT/EP2005/007457 EP2005007457W WO2006008008A3 WO 2006008008 A3 WO2006008008 A3 WO 2006008008A3 EP 2005007457 W EP2005007457 W EP 2005007457W WO 2006008008 A3 WO2006008008 A3 WO 2006008008A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
hnf4a
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/007457
Other languages
French (fr)
Other versions
WO2006008008A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2006008008A2 publication Critical patent/WO2006008008A2/en
Publication of WO2006008008A3 publication Critical patent/WO2006008008A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human HNF4A which is associated with the gastrointestinal and liver diseases, cancer disorders, cardiovascular disorders, metabolic diseases, inflammatory diseases, muscle-skeleton disorders, respiratory diseases, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of gastrointestinal and liver diseases, cancer disorders, cardiovascular disorders, metabolic diseases, inflammatory diseases, muscle-skeleton disorders, respiratory diseases, reproduction disorders and urological disorders.. The invention also features compounds which bind to and/or activate or inhibit the activity of HNF4A as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007457 2004-07-23 2005-07-09 Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a) WO2006008008A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017447.6 2004-07-23
EP04017447 2004-07-23

Publications (2)

Publication Number Publication Date
WO2006008008A2 WO2006008008A2 (en) 2006-01-26
WO2006008008A3 true WO2006008008A3 (en) 2006-06-22

Family

ID=35618139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007457 WO2006008008A2 (en) 2004-07-23 2005-07-09 Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)

Country Status (1)

Country Link
WO (1) WO2006008008A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9981048B2 (en) 2013-02-12 2018-05-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for the treatment and prevention of liver disease
EP4519685A1 (en) * 2022-05-01 2025-03-12 Yeda Research and Development Co. Ltd Reexpression of hnf4a to alleviate cancer-associated cachexia

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023780A1 (en) * 1996-11-26 1998-06-04 Joslin Diabetes Center, Inc. Methods for diagnosing and treating diabetes
US6025196A (en) * 1990-12-21 2000-02-15 The Rockefeller University Chimeric proteins comprising liver enriched transcription factors and nucleic acids encoding the same
WO2002024227A1 (en) * 2000-09-20 2002-03-28 Kyowa Hakko Kogyo Co., Ltd. Tumor cell proliferation inhibitors
WO2002072874A1 (en) * 2001-03-14 2002-09-19 Fujisawa Pharmaceutical Co., Ltd. METHOD OF SCREENING HNF4α AGONIST
WO2003016559A2 (en) * 2001-08-17 2003-02-27 Novo Nordisk A/S Method for treating diabetes based on the modulation of nh4alpha gene expression
WO2003064628A2 (en) * 2002-02-01 2003-08-07 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025196A (en) * 1990-12-21 2000-02-15 The Rockefeller University Chimeric proteins comprising liver enriched transcription factors and nucleic acids encoding the same
WO1998023780A1 (en) * 1996-11-26 1998-06-04 Joslin Diabetes Center, Inc. Methods for diagnosing and treating diabetes
WO2002024227A1 (en) * 2000-09-20 2002-03-28 Kyowa Hakko Kogyo Co., Ltd. Tumor cell proliferation inhibitors
WO2002072874A1 (en) * 2001-03-14 2002-09-19 Fujisawa Pharmaceutical Co., Ltd. METHOD OF SCREENING HNF4α AGONIST
WO2003016559A2 (en) * 2001-08-17 2003-02-27 Novo Nordisk A/S Method for treating diabetes based on the modulation of nh4alpha gene expression
WO2003064628A2 (en) * 2002-02-01 2003-08-07 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics

Also Published As

Publication number Publication date
WO2006008008A2 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2005075665A3 (en) Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2004104215A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7)
WO2006008002A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2006008008A3 (en) Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005106471A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
WO2005103702A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
WO2005118840A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
WO2005078117A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
WO2005103711A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)
WO2005103690A3 (en) Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2004104595A3 (en) Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd)
WO2005083105A3 (en) Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
WO2004106536A3 (en) Diagnostics and therapeutics for diseases associated with serine protease 8 (prss8)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase